Vytrus Biotech (FRA:V5P) GF Score: 63/100 (As of Jul. 10, 2026) — 133% Above Median


FRA:V5P Vytrus Biotech SA FRA:V5P
63 GF Score
Price €16.70
GF Value €6.81
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech GF Score?

Vytrus Biotech FRA:V5P -2.34% 63 GF Score is 63 as of Jul. 10, 2026, which is 133% above its 10-year median of 27.00. GuruFocus rates FRA:V5P with a GF Score™ of 63/100 and a GF Value™ of €6.81 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Vytrus Biotech has the GF Score of 63, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 8/10
3. Growth Rank : 7/10
4. GF Value Rank : 1/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Vytrus Biotech might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Vytrus Biotech  (FRA:V5P) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Vytrus Biotech GF Score Related Terms

FRA:V5P vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Vytrus Biotech's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vytrus Biotech GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vytrus Biotech's GF Score distribution charts can be found below:

* The bar in red indicates where Vytrus Biotech's GF Score falls into.


FRA:V5P
63GF Score
Vytrus Biotech SA FRA:V5P
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 63 mean?
Vytrus Biotech (FRA:V5P) has a GF Score of 63 as of Jul. 10, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Vytrus Biotech and its competitors. This is 133% above median its historical median of 27.00. Over the past decade, Vytrus Biotech's GF Score has ranged from 5.00 to 76.00.
Is Vytrus Biotech's GF Score too high?
Vytrus Biotech's current GF Score of 63 is 133% above median its 10-year median of 27.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 76.00. Overall, Vytrus Biotech has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's GF Score compare to VRTX and REGN?
Vytrus Biotech's GF Score of 63 can be compared against companies in the Biotechnology industry. Historically, Vytrus Biotech's own GF Score has ranged from 5.00 to 76.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current GF Score is 63, which is 133% above median its own 10-year median of 27.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.81, compared to a current price of €16.70 — trading 145.2% above its estimated fair value. The current GF Score is 63, which is 133% above median its 10-year median of 27.00. Vytrus Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current GF Score is 63 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.70 is trading 145.2% above its estimated GF Value™ of €6.81. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for FRA:V5P:

  • GF Score: 63 (133% above median its 10-year median of 27.00)
  • GF Value™: €6.81 vs. price of €16.70 (145.2% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges VYT:Spain
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
63GF Score

Get the complete analysis for FRA:V5P

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€6.81
GF Value